H.C. Wainwright reiterates buy rating on Kura Oncology stock at $40

H.C. Wainwright reiterated its buy rating and $40 price target on Kura Oncology (KURA) following positive Phase 1a/1b KOMET-007 trial data presented at the European Hematology Association meeting, showing ziftomenib's favorable safety profile and high response rates in newly diagnosed AML patients. The trial demonstrated a 92% complete remission composite rate in first-line treatment, and the FDA has accepted the New Drug Application for ziftomenib with priority review. Kura plans to initiate pivotal Phase 3 trials in the second half of 2025, supported by a strong cash position of $703.2 million.

Analysis

H.C. Wainwright has reaffirmed its buy rating and a $40 price target for Kura Oncology (NASDAQ:KURA), a significant premium to its current trading price of $6.66, despite the stock's 69% decline over the past year. This optimism is primarily driven by updated clinical trial results for ziftomenib presented at the European Hematology Association meeting. The Phase 1a/1b KOMET-007 trial, involving 82 newly diagnosed acute myeloid leukemia (AML) patients with NPM1 mutations (49 patients) or KMT2A rearrangements (33 patients), demonstrated ziftomenib's favorable safety profile when combined with standard 7+3 chemotherapy, showing no dose-limiting toxicities and minimal QTc prolongation or differentiation syndrome events. Importantly, the trial reported high rates of composite complete response (92% in first-line treatment) and minimal residual disease negativity, positioning ziftomenib as a potential early intervention. Further bolstering the outlook, Kura Oncology maintains a robust financial position, with more cash than debt, a current ratio of 8.07x, and a pro forma cash reserve of $703.2 million. The company is preparing for pivotal Phase 3 trials (KOMET-017-IC and KOMET-017-NIC) in newly diagnosed patients, slated to begin in the second half of 2025. Additional positive data emerged from the Phase 2 KOMET-001 trial for relapsed or refractory NPM1-mutant AML, which showed a 23% complete remission rate and a 63% minimal residual disease-negative rate. The U.S. Food and Drug Administration has accepted the New Drug Application for ziftomenib, granting it priority review with a Prescription Drug User Fee Act (PDUFA) date set for November 30, 2025. This regulatory milestone, coupled with a consensus "Strong Buy" from analysts and InvestingPro’s Fair Value analysis suggesting undervaluation, underscores the developmental progress despite recent market performance. Other firms, including Citizens JMP, Leerink Partners, and Cantor Fitzgerald, have also reiterated positive ratings.

Key Decisions for Investors

• Investors should note the substantial disparity between analyst price targets, such as H.C. Wainwright's $40, and Kura Oncology's current stock price, which, combined with positive clinical data and a strong financial position, may indicate significant upside potential if clinical and regulatory milestones are met.
• Key upcoming catalysts to monitor include the initiation of pivotal Phase 3 trials in the second half of 2025, further data releases from combination studies, and particularly the FDA's PDUFA decision on ziftomenib by November 30, 2025, which will be critical for the company's trajectory.
• Given the promising trial results, FDA priority review, and strong analyst sentiment against a backdrop of a significantly depressed stock price, investors with a suitable risk appetite for biotech investments might consider current levels as a potential entry point, while remaining cognizant of the inherent clinical development and regulatory approval risks.